Andrew Hirsch

CIK: 0001586707

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)4 (28.6%)

Derivative conversions

Awards (A)4 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)6 (42.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

EDIT

Editas Medicine, Inc.

Director

CCCC

C4 Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

EDIT
Editas Medicine, Inc.
Jun 17, 2026
Award(A)
Stock Option (right to buy)
Direct
51.7K shares-
CCCC
C4 Therapeutics, Inc.
Feb 15, 2026
Tax Payment(F)
Direct
9.1K shares at avg. $1.89$17K
CCCC
C4 Therapeutics, Inc.
Feb 15, 2026
Exercise(M)
Direct
20.4K shares-
CCCC
C4 Therapeutics, Inc.
Feb 14, 2026
Exercise(M)
Direct
81.7K shares-
CCCC
C4 Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
39.2K shares at avg. $1.89$74K
CCCC
C4 Therapeutics, Inc.
Feb 13, 2026
Award(A)
Direct
700K shares-
EDIT
Editas Medicine, Inc.
Jun 6, 2025
Award(A)
Stock Option (right to buy)
Direct
37.5K shares-
CCCC
C4 Therapeutics, Inc.
Feb 15, 2025
Tax Payment(F)
Direct
9.4K shares at avg. $3.18$30K
CCCC
C4 Therapeutics, Inc.
Feb 14, 2025
Award(A)
Direct
223.5K shares-
CCCC
C4 Therapeutics, Inc.
Feb 14, 2025
Tax Payment(F)
Direct
12.8K shares at avg. $3.18$41K
CCCC
C4 Therapeutics, Inc.
Nov 7, 2024
Exercise(M)
Direct
12.5K shares-
CCCC
C4 Therapeutics, Inc.
Nov 7, 2024
Tax Payment(F)
Direct
5.6K shares at avg. $6.04$34K
CCCC
C4 Therapeutics, Inc.
Sep 16, 2024
Exercise(M)
Direct
7.5K shares-
CCCC
C4 Therapeutics, Inc.
Sep 16, 2024
Tax Payment(F)
Direct
3.3K shares at avg. $6.36$21K

		Type	Shares	Price		Ownership
Jun 17, 2026	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	51,700	-	-	Direct
Feb 15, 2026	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	9,057	$1.89	$17,118	Direct
Feb 15, 2026	CCCC C4 Therapeutics, Inc.	Exercise(M)	20,400	-	$0	Direct
Feb 14, 2026	CCCC C4 Therapeutics, Inc.	Exercise(M)	81,725	-	$0	Direct
Feb 14, 2026	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	39,154	$1.89	$74,001	Direct
Feb 13, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	700,000	-	$0	Direct
Jun 6, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	37,500	-	-	Direct
Feb 15, 2025	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	9,370	$3.18	$29,797	Direct
Feb 14, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	223,500	-	-	Direct
Feb 14, 2025	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	12,847	$3.18	$40,853	Direct
Nov 7, 2024	CCCC C4 Therapeutics, Inc.	Exercise(M)	12,500	-	$0	Direct
Nov 7, 2024	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	5,550	$6.04	$33,522	Direct
Sep 16, 2024	CCCC C4 Therapeutics, Inc.	Exercise(M)	7,500	-	$0	Direct
Sep 16, 2024	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	3,329	$6.36	$21,172	Direct

1-14 of 14 transactions

About Hirsch Andrew

Hirsch Andrew (SEC CIK 0001586707) files insider reports with the SEC as Director of Editas Medicine, Inc. (EDIT) and President & CEO of C4 Therapeutics, Inc. (CCCC).

Signal8 holds 6 ownership filings by Hirsch Andrew, all Form 4s, filed between Sep 17, 2024 and Jun 22, 2026. Those filings report 14 transactions, from Sep 16, 2024 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hirsch Andrew's filings is in CAMBRIDGE, MA.

Recent filings by Hirsch Andrew

Jun 17, 2026: Grant or award of EDIT derivative securities (Form 4, code A).
Feb 15, 2026: Tax withholding of CCCC shares (Form 4, code F).
Feb 15, 2026: Option exercise of CCCC shares (Form 4, code M).
Feb 14, 2026: Option exercise of CCCC shares (Form 4, code M).
Feb 14, 2026: Tax withholding of CCCC shares (Form 4, code F).

Other insiders filing for Editas Medicine, Inc. (EDIT)

Ory Daniel Scott, EVP, Chief Medical Officer
Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER
Parison Amy, SVP, Chief Financial Officer
O'Neill Gilmore Neil, CEO
Ellinor Patrick Thomas II, Director
Connaughton Bernadette, Director

How to read Form 4 transaction codes